Page 43 - AN-2-3

Advanced Neurology Multiple sclerosis: Immunopathogenesis

treatment. Brain, 140: 527–546. 53. Williams T, Zetterberg H, Chataway J, 2021, Neurofilaments
in progressive multiple sclerosis: A systematic review.
https://doi.org/10.1093/brain/aww258
J Neurol, 268: 3212–3222.
42. Bodini B, Veronese M, García-Lorenzo D, et al., 2016,
Dynamic imaging of individual remyelination profiles in https://doi.org/10.1007/s00415-020-09917-x
multiple sclerosis. Ann Neurol, 79: 726–738. 54. Pitt D, Lo CH, Gauthier SA, et al., 2022, Toward precision
https://doi.org/10.1002/ana.24620 phenotyping of multiple sclerosis. Neurol Neuroimmunol
Neuroinflamm, 9: e200025.
43. Franklin RJM, Frisén J, Lyons DA, 2021, Revisiting
remyelination: Towards a consensus on the regeneration of https://doi.org/10.1212/NXI.0000000000200025
CNS myelin. Semin Cell Dev Biol, 116: 3–9. 55. Siller N, Kuhle J, Muthuraman M, et al., 2019, Serum
https://doi.org/10.1016/j.semcdb.2020.09.009 neurofilament light chain is a biomarker of acute and
chronic neuronal damage in early multiple sclerosis. Mult
44. Schattling B, Engler JB, Volkmann C, et al., 2019, Bassoon Scler, 25: 678–686.
proteinopathy drives neurodegeneration in multiple
sclerosis. Nat Neurosci, 22: 887–896. https://doi.org/10.1177/1352458518765666
https://doi.org/10.1038/s41593-019-0385-4 56. Bjornevik K, Munger KL, Cortese M, et al., 2020,
Serum neurofilament light chain levels in patients with
45. Luchicchi A, Hart B, Frigerio I, et al., 2021, Axon-myelin presymptomatic multiple sclerosis. JAMA Neurol, 77: 58–64.
unit blistering as early event in MS normal appearing white
matter. Ann Neurol, 89: 711–725. https://doi.org/10.1001/jamaneurol.2019.3238
https://doi.org/10.1002/ana.26014 57. Kapoor R, Smith KE, Allegretta M, et al., 2020, Serum
neurofilament light as a biomarker in progressive multiple
46. Schumacher AM, Mahler C, Kerschensteiner M, 2017, sclerosis. Neurology, 95: 436–444.
Pathology and pathogenesis of progressive multiple sclerosis:
Concepts and controversies. Neurol Int Open, 1: E171–E181. https://doi.org/10.1212/WNL.0000000000010346
https://doi.org/10.1055/s-0043-106704 58. Golabi M, Fathi F, Samadi M, et al., 2022, Identification of
potential biomarkers in the peripheral blood mononuclear
47. He A, Merkel B, Brown JWL, et al., 2020, Timing of high- cells of relapsing-remitting multiple sclerosis patients.
efficacy therapy for multiple sclerosis: A retrospective Inflammation, 45: 1815–1828.
observational cohort study. Lancet Neurol, 19: 307–316.
https://doi.org/10.1007/s10753-022-01662-9
https://doi.org/10.1016/S1474-4422(20)30067-3
59. Abdelhak A, Huss A, Kassubek J, et al., 2018, Serum GFAP
48. Tavazzi E, Zivadinov R, Dwyer MG, et al., 2020, MRI as a biomarker for disease severity in multiple sclerosis. Sci
biomarkers of disease progression and conversion to Rep, 8: 14798.
secondary-progressive multiple sclerosis. Expert Rev
Neurother, 20: 821–834. https://doi.org/10.1038/s41598-018-33158-8
https://doi.org/10.1080/14737175.2020.1757435 60. Hou Y, Dan X, Babbar M, et al., 2019, Ageing as a risk factor
for neurodegenerative disease. Nat Rev Neurol, 15: 565–581.
49. Filippi M, Preziosa P, Langdon D, et al., 2020, Identifying
progression in multiple sclerosis: New perspectives. Ann https://doi.org/10.1038/s41582-019-0244-7
Neurol, 88: 438–452.
61. Krysko KM, Henry RG, Cree BA, et al., 2019, Telomere
https://doi.org/10.1002/ana.25808 length is associated with disability progression in multiple
sclerosis. Ann Neurol, 86: 671–682.
50. Frischer JM, Weigand SD, Guo Y, et al., 2015, Clinical and
pathological insights into the dynamic nature of the white https://doi.org/10.1002/ana.25592
matter multiple sclerosis plaque. Ann Neurol, 78: 710–721.
62. Meca-Lallana V, Berenguer-Ruiz L, Carreres-Polo J, et al.,
https://doi.org/10.1002/ana.24497 2021, Deciphering multiple sclerosis progression. Front
51. Absinta M, Sati P, Masuzzo F, et al., 2019, Association of Neurol, 12: 608491.
chronic active multiple sclerosis lesions with disability in https://doi.org/10.3389/fneur.2021.608491
vivo. JAMA Neurol, 76: 1474–1483.
63. Sandelius Å, Sandgren S, Axelsson M, et al., 2019,
https://doi.org/10.1001/jamaneurol.2019.2399 Cerebrospinal fluid growth-associated protein 43 in multiple
52. Kaisey M, Lashgari G, Fert-Bober J, et al., 2022, An update sclerosis. Sci Rep, 9: 17309.
on diagnostic laboratory biomarkers for multiple sclerosis. https://doi.org/10.1111/j.1365-2990.2006.00730.x
Curr Neurol Neurosci Rep, 22: 675–688.
64. Shah AA, Piche J, Stewart B, et al., 2023, Limited diagnostic
https://doi.org/10.1007/s11910-022-01227-1 utility of serologic testing for neurologic manifestations of

Volume 2 Issue 3 (2023) 12 https://doi.org/10.36922/an.1319